Edition:
United Kingdom

Chiasma Inc (CHMA.OQ)

CHMA.OQ on NASDAQ Stock Exchange Global Select Market

1.85USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
15,468
52-wk High
$2.95
52-wk Low
$1.25

Chart for

About

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial... (more)

Overall

Beta: --
Market Cap(Mil.): $70.64
Shares Outstanding(Mil.): 24.36
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Chiasma Q3 loss per share $0.28

* Chiasma Inc - ‍ cash, cash equivalents & marketable securities as of Sept 30, 2017 were $73.2 million, compared with $93.0 million as of December 31, 2016​ Source text for Eikon: Further company coverage:

09 Nov 2017

BRIEF-Chiasma announces first patient is randomized in phase 3 trial of Octreotide capsules in patients with acromegaly

* Chiasma announces first patient is randomized in phase 3 chiasma optimal clinical trial of Octreotide capsules in patients with acromegaly

27 Sep 2017

BRIEF-Chiasma reached deal with FDA on late-stage trial of its acromegaly drug

* Chiasma reaches agreement with FDA under special protocol assessment for a new phase 3 clinical trial of octreotide capsules in acromegaly

10 Aug 2017

Earnings vs. Estimates